HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations

As drugmakers continue to battle President Biden’s HHS in court over alleged 340B drug discount violations, HHS sent letters on Wednesday to six companies informing them that their violations have been referred to the HHS Office of the Inspector General, which can levy $5,000 fines each.